According to Atara Biotherapeutics's latest financial reports the company has a price-to-book ratio of -0.8616.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | -0.5267 | -121.43% |
2022-12-31 | 2.46 | -52.44% |
2021-12-31 | 5.17 | 45.97% |
2020-12-31 | 3.54 | 10.02% |
2019-12-31 | 3.22 | -31.7% |
2018-12-31 | 4.71 | 51.31% |
2017-12-31 | 3.11 | 92.77% |
2016-12-31 | 1.62 | -32.29% |
2015-12-31 | 2.39 | -53.28% |
2014-12-31 | 5.11 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
ImmunoGen
IMGN | 15.5 | -1,903.04% | ๐บ๐ธ USA |
Agenus
AGEN | -1.57 | 82.65% | ๐บ๐ธ USA |
Affimed
AFMD | 1.23 | -242.69% | ๐ฉ๐ช Germany |